Press releaseBusiness Wire
Sarepta Therapeutics
SRPT · NASDAQ
$19.17+$1.44 (+8.12%)TodayMarket closed ·
Prev close $17.73
Latest news
- NewsAvi Kapoor
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’
- Press releaseBusiness Wire
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
- Press releaseBusiness Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
- Press releaseBusiness Wire
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
- Press releaseBusiness Wire
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
- NewsAvi Kapoor
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
- NewsVandana Singh
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
- Press releaseBusiness Wire
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
- NewsAvi Kapoor
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Press releasePRNewswire
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
- Press releaseBusiness Wire
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Press releaseBusiness Wire
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
- News
Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate
- Press releaseBusiness Wire
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
- Press releaseBusiness Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
- Press releaseBusiness Wire
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)
- Press releaseBusiness Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewsVandana Singh
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
- Press releaseBusiness Wire
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
- NewsPiero Cingari
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today
- Press releaseGlobe Newswire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
- Press releaseBusiness Wire
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
- News
Earnings Scheduled For May 6, 2026
- Press releaseBusiness Wire
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
- Press releaseBusiness Wire
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
- Press releaseBusiness Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewsAvi Kapoor
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast
- NewsAvi Kapoor
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsPiero Cingari
Stocks Rise, Oil Falls On Iran Ceasefire Hopes, ARM Surges 15% : What's Moving Markets Wednesday?
- NewsAvi Kapoor
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday
- NewsAvi Kapoor
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
- NewsChris Katje
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
- NewsChris Katje
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?
- NewsAvi Kapoor
This Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.